药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Zuclopenthixol
Odesivimab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Odesivimab.
Zuclopenthixol
Maftivimab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Maftivimab.
Zuclopenthixol
Atoltivimab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Atoltivimab.
Zuclopenthixol
Zenocutuzumab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Zenocutuzumab.
Zuclopenthixol
Naratuximab emtansine
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Naratuximab emtansine.
Zuclopenthixol
Lorukafusp alfa
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Lorukafusp alfa.
Zuclopenthixol
Lulizumab pegol
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Lulizumab pegol.
Zuclopenthixol
Pinatuzumab vedotin
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Pinatuzumab vedotin.
Zuclopenthixol
Vesencumab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Vesencumab.
Zuclopenthixol
Tomaralimab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Tomaralimab.
Zuclopenthixol
Ladiratuzumab vedotin
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Ladiratuzumab vedotin.
Zuclopenthixol
GMA-161
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with GMA-161.
Zuclopenthixol
Pidilizumab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Pidilizumab.
Zuclopenthixol
Istiratumab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Istiratumab.
Zuclopenthixol
Evinacumab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Evinacumab.
Zuclopenthixol
Sofituzumab vedotin
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Sofituzumab vedotin.
Zuclopenthixol
Valanafusp alfa
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Valanafusp alfa.
Zuclopenthixol
Gedivumab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Gedivumab.
Zuclopenthixol
Bleselumab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Bleselumab.
Zuclopenthixol
Nemolizumab
The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Nemolizumab.